Keryx And Akebia Unite to Create a Chronic Kidney Disease Specialist
By Subham Nandi
Pharma Deals Review: Vol 2018 Issue 7 (Table of Contents)
Published: 19 Jul-2018
DOI: 10.3833/pdr.v2018.i7.2336 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
Based on their synergies in renal disorders, Keryx Biopharmaceuticals and Akebia Therapeutics have announced a merger in an all stock deal to form a company specialised in chronic kidney diseases (CKD)...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS